Jacobi Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Jacobi Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-218	Closed	-$16K	–	476
2021 Q3	$16K	Buy	218 +15	+7%	+$1.26K	﹤0.01%	931
2021 Q2	$19K	Hold	203	–	–	﹤0.01%	840
2021 Q1	$18K	Buy	+203	New	+$20.1K	﹤0.01%	800

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Jacobi Capital Management's ARKG Position: Q4 2021 in Review

Jacobi Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 218 shares — an estimated $16K sold.

Jacobi Capital Management first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $19K in Q2 2021. 462 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

Jacobi Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 218 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $16K.
Jacobi Capital Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
Jacobi Capital Management's ARK Genomic Revolution ETF position peaked at $19K in Q2 2021.
462 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.